CommurePRIVATE · FOUNDED 2017Each bar is the last disclosed mark — $1B for Alloy Therapeutics (post-money, Apr 2026) and $7B for Commure (post-money, May 2026).

CommurePRIVATEHealth · US · 2017
The $7B tells you…Both marks are post-money, so 7.00× compares like with like. Both are private: there is no public quote and no Canborsa market on either name.
Alloy Therapeutics' sector is Biotech; Commure's sector is Healthcare AI / operations software.
Alloy Therapeutics is valued at $1B, and Commure at $7B.
Alloy Therapeutics' most recent round was Series E, raising $40M in April 2026; Commure's was Series Funding, raising $70M in May 2026.
Alloy Therapeutics was founded in 2011, and Commure was founded in 2017.